Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will present a company ove...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts have been accepted...
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is the focus of IBN's latest stock spotlight. The company's shares have moved 11.46% on the day to $14.2. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's p...
2024-02-23 16:23:17 ET More on ORIC Pharmaceuticals ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting ORIC Pharmaceuticals stock rises after it announces $125M private placement Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historica...
SOUTH SAN FRANCISCO and SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat...
2024-01-26 17:08:20 ET More on ORIC Pharmaceuticals ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting ORIC Pharmaceuticals stock rises after it announces $125M private placement Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historica...
2024-01-22 08:44:33 ET More on ORIC Pharmaceuticals ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historical earnings data for ORIC Pharmaceuticals Financial information for ORIC Phar...
Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), and Nextech Pro forma cash and investments expected to fund current operating plan into late 2026 ...
2024-01-09 12:31:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Under most financial guidance frameworks, experts advise a long-term approach, which is exactly the opposite ethos when it comes to speculative ideas for high potential stocks. Here, the emphas...
Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination development Initiation of combi...
News, Short Squeeze, Breakout and More Instantly...
Oric Pharmaceuticals Inc. Company Name:
ORIC Stock Symbol:
NASDAQ Market:
2024-05-13 04:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best...
2024-05-03 09:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...